Small Molecules

Dodson J, Lio PA. Biologics and Small Molecule Inhibitors: an Update in Therapies for Allergic and Immunologic Skin Diseases. Curr Allergy Asthma Rep. 2022;22(12):183-193. doi:10.1007/s11882-022-01047-w

Damsky W, Peterson D, Ramseier J, et al. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. Journal of Allergy and Clinical Immunology. 2021;147(3):814-826. doi:10.1016/j.jaci.2020.10.022

Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert Opinion on Drug Safety. 2023;22(1):43-58. doi:10.1080/14740338.2023.2173171

Sreekantaswamy SA, Tully J, Edelman LS, Supiano MA, Butler D. The underrepresentation of older adults in clinical trials of Janus kinase inhibitors in the treatment of atopic dermatitis. Journal of the American Academy of Dermatology. 2022;87(5):1174-1176. doi:10.1016/j.jaad.2022.02.051

Megna M, Potestio L, Fabbrocini G, Camela E. Treating psoriasis in the elderly: biologics and small molecules. Expert Opinion on Biological Therapy. 2022;22(12):1503-1520. doi:10.1080/14712598.2022.2089020

Nassim D, Alajmi A, Jfri A, Pehr K. Apremilast in dermatology: A review of literature. Dermatologic Therapy. 2020;33(6). doi:10.1111/dth.14261

Schafer P, Parton A, Gandhi A, et al. Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasis. British J Pharmacology. 2010;159(4):842-855. doi:10.1111/j.1476-5381.2009.00559.x

Nast A, Spuls PI, Van Der Kraaij G, et al. European S3‐Guideline on the systemic treatment of psoriasis vulgaris – Update Apremilast and Secukinumab – EDF in cooperation with EADV and IPC. Acad Dermatol Venereol. 2017;31(12):1951-1963. doi:10.1111/jdv.14454

Bakirtzi K, Sotiriou E, Papadimitriou I, et al. Elderly patients with psoriasis: long-term efficacy and safety of modern treatments. Journal of Dermatological Treatment. 2022;33(3):1339-1342. doi:10.1080/09546634.2020.1809623

Phan C, Beneton N, Delaunay J, et al. Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis. Drugs Aging. 2020;37(9):657-663. doi:10.1007/s40266-020-00781-y

Crowley J, Thaçi D, Joly P, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). Journal of the American Academy of Dermatology. 2017;77(2):310-317.e1. doi:10.1016/j.jaad.2017.01.052

Megna M, Fabbrocini G, Camela E, Cinelli E. Apremilast efficacy and safety in elderly psoriasis patients over a 48‐week period. Acad Dermatol Venereol. 2020;34(11). doi:10.1111/jdv.16443

Mansilla-Polo M, Gimeno E, Morgado-Carrasco D. [Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review. Actas Dermo-Sifiliográficas. 2024;115(3):T265-T279. doi:10.1016/j.ad.2024.01.009

Müller S, Maintz L, Bieber T. Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs. Allergy. 2024;79(6):1501-1515. doi:10.1111/all.16009

Carmona-Rocha E, Rusiñol L, Puig L. New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis. Pharmaceutics. 2024;16(2):239. doi:10.3390/pharmaceutics16020239

Klein B, Treudler R, Simon JC. JAK‐inhibitors in dermatology – small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects. J Deutsche Derma Gesell. 2022;20(1):19-24. doi:10.1111/ddg.14668

Yoon S, Kim K, Shin K, et al. The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta‐analysis of randomized controlled trials. Acad Dermatol Venereol. 2024;38(1):52-61. doi:10.1111/jdv.19426

Maurelli M, Chiricozzi A, Peris K, Gisondi P, Girolomoni G. Atopic Dermatitis in the Elderly Population. Acta Derm Venereol. 2023;103:adv13363. doi:10.2340/actadv.v103.13363

Adam DN, Gooderham MJ, Beecker JR, et al. Expert consensus on the systemic treatment of atopic dermatitis in special populations. Acad Dermatol Venereol. 2023;37(6):1135-1148. doi:10.1111/jdv.18922

Winthrop KL, Cohen SB. Oral surveillance and JAK inhibitor safety: the theory of relativity. Nat Rev Rheumatol. 2022;18(5):301-304. doi:10.1038/s41584-022-00767-7

Tavoletti G, Avallone G, Conforti C, et al. Topical ruxolitinib: A new treatment for vitiligo. Acad Dermatol Venereol. 2023;37(11):2222-2230. doi:10.1111/jdv.19162

Samuel C, Cornman H, Kambala A, Kwatra SG. A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring. Dermatol Ther (Heidelb). 2023;13(3):729-749. doi:10.1007/s13555-023-00892-5

Cline A, Cardwell LA, Feldman SR. Advances in treating psoriasis in the elderly with small molecule inhibitors. Expert Opinion on Pharmacotherapy. 2017;18(18):1965-1973. doi:10.1080/14656566.2017.1409205

Kleinman E, Laborada J, Metterle L, Eichenfield LF. What’s New in Topicals for Atopic Dermatitis? Am J Clin Dermatol. 2022;23(5):595-603. doi:10.1007/s40257-022-00712-0

Zhang L, Guo L, Wang L, Jiang X. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis – A network meta‐analysis. Acad Dermatol Venereol. 2022;36(11):1937-1946. doi:10.1111/jdv.18263

Nash P, Kerschbaumer A, Dörner T, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021;80(1):71-87. doi:10.1136/annrheumdis-2020-218398

Rudnicka L, Arenbergerova M, Grimalt R, et al. European expert consensus statement on the systemic treatment of alopecia areata. Acad Dermatol Venereol. 2024;38(4):687-694. doi:10.1111/jdv.19768

Betancourt BY, Biehl A, Katz JD, Subedi A. Pharmacotherapy Pearls in Rheumatology for the Care of Older Adult Patients. Rheumatic Disease Clinics of North America. 2018;44(3):371-391. doi:10.1016/j.rdc.2018.03.010

Rajasimhan S, Pamuk O, Katz JD. Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk. Drugs Aging. 2020;37(8):551-558. doi:10.1007/s40266-020-00775-w

Mansilla-Polo M, Morgado-Carrasco D. Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review. Dermatol Ther (Heidelb). Published online July 16, 2024. doi:10.1007/s13555-024-01203-2

Mansilla-Polo M, Morgado-Carrasco D. Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review. Dermatol Ther (Heidelb). 2024;14(6):1389-1442. doi:10.1007/s13555-024-01166-4

Wohlrab J, Kegel T, Große R, Eichner A. Recommendations for risk minimization when using Janus kinase inhibitors for the treatment of chronic inflammatory skin diseases. J Deutsche Derma Gesell. 2023;21(8):845-851. doi:10.1111/ddg.15136

Baumrin E, Van Voorhees A, Garg A, Feldman SR, Merola JF. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 2019;81(1):102-110. doi:10.1016/j.jaad.2019.03.017